New Two-Drug attack targets Tough-to-Treat cancer mutation
NCT ID NCT05907304
Summary
This study is testing the safety and early effectiveness of a new drug combination (naporafenib plus trametinib) for people with advanced solid tumors that have a specific genetic change called a RAS Q61X mutation. It is for patients aged 12 and older whose cancer has grown despite standard treatments or for whom no standard treatment exists. The main goals are to see if the treatment shrinks tumors and to understand its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Center
Glasgow, United Kingdom
-
British Columbia Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
-
Comprehensive Cancer Center of Nevada (CCCN)
Las Vegas, Nevada, 89169, United States
-
Cross Cancer Institute- Alberta Health Services (AHS)
Edmonton, Alberta, T6G 1Z2, Canada
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
Florida Cancer Specialists - Sarasota
Sarasota, Florida, 34232, United States
-
Florida Cancer Specialists - St. Petersburg
St. Petersburg, Florida, 33705, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Inje University Haeundae Paik Hospital
Busan, Busan Gwang'yeogsi, 48108, South Korea
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Linear Clinical Research, LTD
Perth, Australia
-
London Regional Cancer Center
London, Ontario, Canada
-
Macquarie University
Macquarie Park, New South Wales, Australia
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
National Cancer Center
Goyang-si, South Korea
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
SCRI Oncology Partners (formerly Tennessee Oncology)
Nashville, Tennessee, 37203, United States
-
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, 06351, South Korea
-
Sarah Cannon Research Institute - HCA Healthcare
City of London, London, W1G 6AD, United Kingdom
-
Seoul National University Hospital
Seoul, South Korea
-
Seoul National University Hospital Bundang
Gyeonggi-do, South Korea
-
St. Vincent's Hospital
Melbourne, Victoria, Australia
-
The Catholic University Hospital
Seoul, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.